Phase IV Thyroid Cancer QOL Study

• Research type

  Research Study

• Full title

  An international phase IV field study for the reliability and validity of the EORTC Thyroid Cancer Module THY34

• IRAS ID

  249595

• Contact name

  Laura Moss

• Contact email

  laura.moss@wales.nhs.uk

• Sponsor organisation

  University Medical Centre Mainz

• Duration of Study in the UK

  0 years, 11 months, 5 days

• Research summary

  Thyroid cancer and its treatments affect quality of life (QoL) across a variety of domains. The EORTC Quality of Life Group therefore developed a module specifically for this group of patients.
  The aim of the present study is to validate the EORTC QLQ-THY34 in a large international field study and to investigate the psychometric properties of its scales.
  The EORTC QLQ-THY34 will be administered to two groups of patients with thyroid cancer. Patients in Group 1 will be approached three times to measure sensitivity to change. The data collection will take place before treatment starts (t1), 6 weeks after the first day of initial treatment (t2), and 6 months after t2 (t3). Patients in Group 2 will complete the questionnaires once (t1) (a minimum of 24 months post diagnosis) and a second time 1 week later (t2) to measure test-retest reliability. The patients will be asked to complete several questionnaires at each measurement point including the EORTC QLQ-C30, the EORTC QLQ-THY34, and the EQ-5D. At t1, they will also be asked to complete a debriefing questionnaire.

• REC name

  Wales REC 7

• REC reference

  19/WA/0056

• Date of REC Opinion

  25 Feb 2019

• REC opinion

  Favourable Opinion